Ally Financial’s AbbVie ABBV Stock Holding History

Ally Financial’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.91M	Hold	18,000	–	–	0.49%	49
2025 Q4	$4.11M	Sell	18,000 -9,000	-33%	-$2.05M	0.5%	44
2025 Q3	$6.25M	Hold	27,000	–	–	0.77%	29
2025 Q2	$5.01M	Buy	+27,000	New	+$5.02M	0.57%	34
2025 Q1	–	Sell	-20,000	Closed	-$3.55M	–	110
2024 Q4	$3.55M	Buy	+20,000	New	+$3.68M	0.43%	48
2024 Q3	–	Sell	-30,000	Closed	-$5.15M	–	108
2024 Q2	$5.15M	Buy	+30,000	New	+$4.97M	0.64%	38
2024 Q1	–	Sell	-20,000	Closed	-$3.1M	–	109
2023 Q4	$3.1M	Sell	20,000 -25,000	-56%	-$3.64M	0.41%	60
2023 Q3	$6.71M	Buy	45,000 +25,000	+125%	+$3.67M	0.99%	26
2023 Q2	$2.69M	Buy	20,000 +9,000	+82%	+$1.32M	0.38%	58
2023 Q1	$1.75M	Hold	11,000	–	–	0.26%	66
2022 Q4	$1.78M	Hold	11,000	–	–	0.28%	73
2022 Q3	$1.48M	Hold	11,000	–	–	0.24%	79
2022 Q2	$1.69M	Buy	+11,000	New	+$1.68M	0.23%	81
2022 Q1	–	Sell	-57,320	Closed	-$7.76M	–	120
2021 Q4	$7.76M	Hold	57,320	–	–	0.71%	36
2021 Q3	$6.18M	Hold	57,320	–	–	0.6%	41
2021 Q2	$6.46M	Hold	57,320	–	–	0.64%	44
2021 Q1	$6.2M	Hold	57,320	–	–	0.59%	41
2020 Q4	$6.14M	Hold	57,320	–	–	0.58%	45
2020 Q3	$5.02M	Hold	57,320	–	–	0.81%	42
2020 Q2	$5.63M	Buy	57,320 +17,320	+43%	+$1.52M	0.93%	32
2020 Q1	$3.05M	Buy	40,000 +10,000	+33%	+$852K	0.33%	63
2019 Q4	$2.66M	Buy	30,000 +15,000	+100%	+$1.25M	0.44%	67
2019 Q3	$1.14M	Hold	15,000	–	–	0.2%	87
2019 Q2	$1.09M	Hold	15,000	–	–	0.19%	90
2019 Q1	$1.21M	Hold	15,000	–	–	0.23%	91
2018 Q4	$1.38M	Hold	15,000	–	–	0.18%	91
2018 Q3	$1.42M	Hold	15,000	–	–	0.28%	84
2018 Q2	$1.39M	Hold	15,000	–	–	0.27%	90
2018 Q1	$1.42M	Buy	+15,000	New	+$1.65M	0.21%	102
2017 Q2	–	Sell	-65,000	Closed	-$4.24M	–	108
2017 Q1	$4.24M	Hold	65,000	–	–	0.95%	33
2016 Q4	$4.07M	Hold	65,000	–	–	0.68%	41
2016 Q3	$4.1M	Sell	65,000 -50,000	-43%	-$3.24M	0.72%	36
2016 Q2	$7.12M	Hold	115,000	–	–	1.19%	24
2016 Q1	$6.57M	Hold	115,000	–	–	0.92%	28
2015 Q4	$6.81M	Buy	115,000 +15,000	+15%	+$864K	0.95%	28
2015 Q3	$5.44M	Buy	+100,000	New	+$6.51M	0.55%	42
2015 Q2	–	Sell	-152,000	Closed	-$8.9M	–	128
2015 Q1	$8.9M	Buy	+152,000	New	+$9.18M	0.92%	35
2014 Q4	–	Sell	-73,000	Closed	-$4.22M	–	130
2014 Q3	$4.22M	Buy	+73,000	New	+$4.05M	0.58%	61
2014 Q2	–	Sell	-155,000	Closed	-$7.97M	–	123
2014 Q1	$7.97M	Buy	+155,000	New	+$7.83M	0.85%	37
2013 Q4	–	Sell	-60,000	Closed	-$2.68M	–	123
2013 Q3	$2.68M	Buy	+60,000	New	+$2.66M	0.29%	98

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ally Financial's ABBV Position: Q1 2026 in Review

Ally Financial held its AbbVie (ABBV) position steady in Q1 2026 at 18,000 shares worth $3.91M. The position accounts for 0.49% of the portfolio, ranked #49.

Ally Financial first reported a position in ABBV in Q3 2013 and has held it in 40 quarters since. The position peaked at $8.9M in Q1 2015. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Ally Financial held 18,000 shares of AbbVie worth $3.91M as of Q1 2026.
Ally Financial left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.49% of Ally Financial's portfolio in Q1 2026, its #49 holding.
Ally Financial first reported a position in AbbVie in Q3 2013 and has held it in 40 quarters since.
Ally Financial's AbbVie position peaked at $8.9M in Q1 2015.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ally Financial's 13F filing for Q1 2026, filed 12 May 2026.